-- 
Partner, Teva and Jerusalem Economy: Israeli Equity Preview

-- B y   R o n i t   G o o d m a n
-- 
2011-04-17T06:31:34Z

-- http://www.bloomberg.com/news/2011-04-17/partner-teva-and-jerusalem-economy-israeli-equity-preview.html
The following stocks may rise or
fall in Israeli markets. Stock symbols are in parentheses after
the company names and prices are from the last close unless
otherwise stated.  The TA-25 Index lost 0.3 percent to 1,326.19 in Tel Aviv.  B Communications Ltd. (BCOM)  : The telecommunications
company expects to receive about 364 million shekels ($106
million) in dividends from Bezeq Israeli Telecommunication Corp.
in May. B Communications slid 2.1 percent to 110 shekels.  Delek The Israeli Fuel Corp. (DLKIS IT): Moody’s Midroog
rated the fuel distributor’s planned 400 million-shekel bond
placement A2 with a stable outlook. The new bonds and previously
rated securities were placed on “watch list. Delek was
unchanged at 115 shekels.  Globe Exploration LP (GLEX IT): The oil and gas explorer
said the drilling start date at Ofek 1 will be postponed to as
late as Aug. 1 because the company needs to import a new
drilling machine. Delek dropped 3.9 percent to 0.05 shekel.  Jerusalem Economy Ltd. (ECJM)  : The real-estate leasing
company said it raised gross proceeds of 199.2 million shekels
from a sale of bonds. Jerusalem Economy lost 0.5 percent to
42.62 shekels.  Partner Communications Co. (PTNR IT): The country’s second-
largest mobile phone company said it’s considering a bond
offering of as much as 1.2 billion shekels. Partner fell 0.4
percent to 63.98 shekels.  Teva Pharmaceutical Industries Ltd. (TEVA)  : The U.S.
 Food and Drug Administration  said the world’s largest maker of
generic drugs’ Lansoprazole may clog oral syringes and feeding
tubes and urged doctors not to dispense the drug in a syringe or
tube.  Separately, Biogen Idec Inc. has identified high-risk
patients taking its multiple sclerosis drug Tysabri who have a 1
percent chance of developing a potentially deadly brain
infection from the medicine. Teva, which makes the Copaxone
multiple sclerosis drug, gained 1.1 percent to 170.40 shekels.  To contact the reporter on this story:
Ronit Goodman in  Tel Aviv  at 
 rgoodman9@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  